This does not seem to be the case for anti-CTLA4 cancer therapy, as feeding Bacteroides fragilis and Burkholderia cepacia to microbiota-depleted mice decreases the extent of intestinal damage and colitis while restoring the therapeutic response to anti-CTLA4 [50]. This evidence concerns the gene CTLA4 and colitis.